A recent phase I clinical trial of the HDAC inhibitor entinostat in combination with 13-cis retinoic acid in 19 patients with solid tumors revealed that the combination treatment was effective at controlling disease progression, although no tumor responses were observed [46]. This evidence concerns the gene HDAC9 and neoplasm.